pharmaphorum August 29, 2024
The £400 million ($529 million) investment programme pledged as part of the new voluntary system of rebates paid by pharma companies in the UK has been announced and will focus mainly on supporting the clinical research sector.
The lion’s share (75%) of the investment money will be made available to set up a network of 18 clinical research hubs – called Commercial Research Delivery Centres (CRDCs) – along with other projects aimed at boosting patient recruitment into studies.
Of the remainder, 20% will go towards initiatives to promote sustainable manufacturing, improving efficiency whilst also reducing waste and emissions, and 5% to a programme to modernise health technology assessment (HTA) processes used to determine the cost-effectiveness of therapies and whether they...
Today's Sponsors
Today's Sponsor